Novel perspective in pancreatic cancer therapy: Targeting ferroptosis pathway

Table 2 Ferroptosis inducers in pancreatic ductal adenocarcinoma

Inducers	Target	Inhibited by	Ref.
Erastin	System XC-/GPX4	CPX	Yang et al[18]
Sulfasalazine	System XC-	β-ME, CHX, DFO, Fer-1, NAC, or Trolox	Kim et al[38,68]
Sorafenib	System XC-	DFO, Fer-1, Trolox, or VE	Lachaier et al[37]
Artesunate	System XC-	DFO or Fer-1	Xie et al[9]
RSL3	GPX4	CPX, DFO, Ebs, Fer-1, Lip-1, Trolox, or U0126	Yang et al[18]
Rapamycin	GPX4	Lip-1	Liu et al[60]
FIN56	GPX4	DFO, BSO and α-Toc	Liang et al[68]
FINO2	GPX4/Iron	β-ME or Fer-1	Liang et al[68]
Piperlongumine	GPX4	Fer-1, lip-1, CPX and DFO	Yamaguchi et al[63]
Ruscogenin	Iron	DFO, FAC	Song et al[59]
Irisin	Iron, ROS, and glutathione depletion	Not mentioned	Yang et al[64]

α-Toc: α-tocopherol; β-ME: β-mercaptoethanol; BSO: Buthionine sulfoximine; CHX: Cycloheximide; CPX: Ciclopirox olamine; DFO: Iron chelator deferoxamine; Ebs: Ebselen; FAC: Ferric ammonium citrate. Fer-1: Ferrostatin-1; Lip-1: Liproxstatin-1; NAC: N-acetylcysteine; VE: Vitamin E.